Skip to content

COVID vaccines show 24 times more adverse reactions than others

Written by Jessie Zhang via The Epoch Times (emphasis ours),

An Australian report on adverse vaccine reactions has revealed that COVID-19 vaccines had 24 times the rate of adverse reactions compared to all other vaccines. (Alberto Pizzoli/AFP via Getty Images)

The latest report on adverse reactions to vaccines in Western Australia has revealed this Vaccines against COVID-19 have 24 times the rate of adverse reactions in the state compared to all other vaccines.

According to the state’s vaccine safety surveillance report (pdf), The COVID-19 vaccines showed that for every 100,000 COVID-19 vaccines administered, 264 adverse events following immunizations (AEFIs) were recorded.

For all other vaccines, an AEFI of 11.1 was recorded, making the COVID-19 vaccines 23.8 times more likely than non-COVID-19 vaccines to cause adverse events.

Table showing number of vaccines administered and adverse events reported, with adverse event rate, for non-COVID-19 vaccines and COVID-19 vaccines, 2021. (Image from Western Australian Department of Health)

The rate of adverse events varied between different types of COVID-19 vaccines.

Spikevax (Moderna) recorded 281.4 AEFI per 100,000 doses, Comirnaty (Pfizer) recorded 244.8, and Vaxzevria (AstraZeneca), which was withdrawn from the vaccine program after reports of clotting blood in younger people.

Post-vaccination adverse events can range from mild, such as a sore arm, to serious conditions, such as anaphylaxis, thrombosis with thrombocytopenia syndrome (TTS), Guillain-Barré syndrome (GBS), myocarditis, and pericarditis.

The collaboration continues with the Super Jab 3 in 1

Meanwhile, despite these concerns, the Australian government’s partnership with Moderna to produce vaccines using experimental messenger RNA technology to prepare for the next pandemic means these vaccines are here to stay.

The company has been forming a trifecta jab to tackle major respiratory viruses — flu, COVID-19 and RSV — to maintain its market share amid falling vaccine company revenue as the health crisis subsides.

Moderna’s $18.4 billion in 2022 COVID-19 vaccine sales are expected to sink to $5 billion this year.

Recently, the authority in Australia obtained accelerated drug approval for its mRNA-1345 (RSV vaccine), which means that the company will be able to launch the vaccines in Australia before any other country in the world.

Registered nurse Emma Ahearn administers the Pfizer COVID-19 vaccine to Millie Persic as she sits on her mother Maria Persic’s lap in Sydney, Australia on January 11, 2022. (Jenny Evans/Getty Images)

A spokesperson for Australia’s Therapeutic Goods Administration told the Epoch Times that Moderna received an expedited approval process on March 30 after meeting all of the following criteria:

  • medicine is new
  • the medicine is for the treatment, prevention or diagnosis of a life-threatening condition
  • no other medicine intended to treat, prevent or diagnose the disease is listed on the Australian Medicines Register or there is substantial evidence that this medicine offers a significant improvement in the effectiveness or safety of treating, preventing or diagnosing the disease compared to goods already included in the register
  • there is substantial evidence that the drug provides a major therapeutic advance.

However, Phase 3 clinical trials for Moderna’s mRNA version of the seasonal flu vaccine have been underwhelming, showing a high rate of side effects.

Although the vaccine generates a strong immune response against A strains of influenza, its effectiveness against B strains is no better than existing approved vaccines.

In addition, 70% of trial participants who received the vaccine reported adverse reactions such as headaches, swelling and fatigue, compared with 48% of the conventional flu vaccine.



Leave a Reply

Your email address will not be published. Required fields are marked *